Morgan Stanley
KALV

Morgan Stanley’s KalVista Pharmaceuticals KALV Stock Holding History

Morgan Stanley’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.84M Sell
439,099
-261,129
-37% -$4.21M ﹤0.01% 3664
2025
Q4 		$11.3M Buy
700,228
+135,372
+24% +$1.79M ﹤0.01% 3506
2025
Q3 		$6.88M Buy
564,856
+325,227
+136% +$4.49M ﹤0.01% 3884
2025
Q2 		$2.71M Buy
239,629
+15,840
+7% +$194K ﹤0.01% 4513
2025
Q1 		$2.58M Sell
223,789
-65,726
-23% -$671K ﹤0.01% 4442
2024
Q4 		$2.45M Sell
289,515
-7,887
-3% -$81.7K ﹤0.01% 4564
2024
Q3 		$3.44M Sell
297,402
-41,182
-12% -$518K ﹤0.01% 4248
2024
Q2 		$3.99M Sell
338,584
-85,850
-20% -$1M ﹤0.01% 4061
2024
Q1 		$5.03M Sell
424,434
-480,434
-53% -$6.41M ﹤0.01% 3907
2023
Q4 		$11.1M Buy
904,868
+694,940
+331% +$6.32M ﹤0.01% 3835
2023
Q3 		$2.02M Buy
209,928
+7,305
+4% +$74.6K ﹤0.01% 4390
2023
Q2 		$1.82M Buy
202,623
+10,847
+6% +$100K ﹤0.01% 4486
2023
Q1 		$1.51M Sell
191,776
-641,977
-77% -$4.79M ﹤0.01% 4619
2022
Q4 		$5.64M Buy
833,753
+802,871
+2,600% +$4.3M ﹤0.01% 3648
2022
Q3 		$448K Sell
30,882
-28,437
-48% -$397K ﹤0.01% 5322
2022
Q2 		$584K Sell
59,319
-8,060
-12% -$88.9K ﹤0.01% 5338
2022
Q1 		$993K Buy
67,379
+4,295
+7% +$61.7K ﹤0.01% 5004
2021
Q4 		$835K Buy
63,084
+45,963
+268% +$732K ﹤0.01% 5200
2021
Q3 		$300K Buy
17,121
+7,306
+74% +$148K ﹤0.01% 5785
2021
Q2 		$235K Sell
9,815
-20,000
-67% -$523K ﹤0.01% 5932
2021
Q1 		$766K Buy
29,815
+17,513
+142% +$460K ﹤0.01% 4895
2020
Q4 		$233K Buy
12,302
+7,250
+144% +$124K ﹤0.01% 5520
2020
Q3 		$63K Sell
5,052
-1,127
-18% -$14.1K ﹤0.01% 5631
2020
Q2 		$75K Sell
6,179
-13,613
-69% -$145K ﹤0.01% 5525
2020
Q1 		$151K Buy
19,792
+896
+5% +$12.1K ﹤0.01% 4998
2019
Q4 		$337K Sell
18,896
-19,423
-51% -$253K ﹤0.01% 5147
2019
Q3 		$444K Buy
38,319
+37,378
+3,972% +$604K ﹤0.01% 4736
2019
Q2 		$21K Sell
941
-6,545
-87% -$153K ﹤0.01% 5914
2019
Q1 		$214K Buy
7,486
+6,636
+781% +$144K ﹤0.01% 5021
2018
Q4 		$17K Sell
850
-3,352
-80% -$67.4K ﹤0.01% 6050
2018
Q3 		$93K Buy
4,202
+3,438
+450% +$46.5K ﹤0.01% 5710
2018
Q2 		$6K Buy
764
+723
+1,763% +$6.38K ﹤0.01% 6402
2018
Q1 		$0 Hold
41
– – ﹤0.01% 6651
2017
Q4 		$0 Hold
41
– – ﹤0.01% 6603
2017
Q3 		$0 Sell
41
-159
-80% -$1.13K ﹤0.01% 6565
2017
Q2 		$1K Hold
200
– – ﹤0.01% 6505
2017
Q1 		$1K Hold
200
– – ﹤0.01% 6499
2016
Q4 		$1K Sell
200
-1
-0.5% -$7 ﹤0.01% 6439
2016
Q3 		$1K Sell
201
-686
-77% -$5.17K ﹤0.01% 6425
2016
Q2 		$8K Buy
887
+474
+115% +$5.49K ﹤0.01% 6106
2016
Q1 		$3K Sell
413
-19
-4% -$341 ﹤0.01% 6358
2015
Q4 		$22K Sell
432
-22
-5% -$1.15K ﹤0.01% 6001
2015
Q3 		$23K Buy
454
+70
+18% +$5.97K ﹤0.01% 6008
2015
Q2 		$38K Buy
+384
New +$38.1K ﹤0.01% 5948

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley's KALV Position: Q1 2026 in Review

Morgan Stanley reduced its KalVista Pharmaceuticals (KALV) stake by 37% in Q1 2026, selling an estimated $4.21M and leaving 439,099 shares worth $8.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3664.

Morgan Stanley first reported a position in KALV in Q2 2015 and has held it in 44 quarters since. The position peaked at $11.3M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Morgan Stanley held 439,099 shares of KalVista Pharmaceuticals worth $8.84M as of Q1 2026.
  • Morgan Stanley sold 261,129 KalVista Pharmaceuticals shares in Q1 2026, an estimated $4.21M.
  • KalVista Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3664 holding.
  • Morgan Stanley first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • Morgan Stanley's KalVista Pharmaceuticals position peaked at $11.3M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.